NCT05939661View on ClinicalTrials.gov

A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2030

Conditions
Rectal Cancer
Interventions
RADIATION

Radiation

Neoadjuvant radiation therapy : 5Gyx5

DRUG

Chemotherapy

CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles

PROCEDURE

Surgery

Operation: Total methorectum excision wiht radical lymph node dissection

Trial Locations (2)

Unknown

RECRUITING

Osaka General Medical Center, Osaka

RECRUITING

Osaka University Hospital, Osaka

All Listed Sponsors
lead

Osaka University

OTHER